Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 2/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596736 | 0.80 | PPARG (0.42) | PPARGPPARAL3MBTL1PTGDR2KDM4E | |
| SCHEMBL5447232 | 0.77 | PPARG (0.45) | PPARGPPARAL3MBTL1PTGDR2ALDH1A1 | |
| SCHEMBL9508809 | 0.74 | MGLL (0.44) | OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL2436091 | 0.70 | MEN1 (0.42) | OXTRAVPR1AHPGDMEN1KMT2A | |
| SCHEMBL31123647 | 0.70 | L3MBTL1 (0.58) | PPARGPPARAL3MBTL1PTGDR2KDM4E | |
| SCHEMBL11274332 | 0.70 | L3MBTL1 (0.58) | PPARGPPARAL3MBTL1PTGDR2KDM4E | |
| SCHEMBL4630498 | 0.69 | PPARG (0.55) | PPARGPPARAL3MBTL1PTGDR2ALDH1A1 | |
| SCHEMBL5438157 | 0.69 | PPARG (0.49) | PPARGPPARAL3MBTL1PTGDR2KDM4E | |
| SCHEMBL4631073 | 0.67 | PPARG (0.51) | PPARGPPARAL3MBTL1PTGDR2KDM4E | |
| SCHEMBL5448702 | 0.67 | PPARG (0.48) | PPARGPPARASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015799-A1 | Glyoxalase inhibitors | GLO1, LOX, LOXL1 | PPARG 4267/4885PPARA 4574/4885L3MBTL1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.